All In Biotech

Drug Trial Radar · NCT05843708

A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Apr 14, 2023

Primary completion

Jul 28, 2023

Study completion Jul 28, 2023

Sponsor

Lead sponsor
Servier Bio-Innovation LLCIndustry
Sponsor type
Industry
Collaborators
Institut de Recherches Internationales Servier
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this study are: * To evaluate the effect of a low-fat meal on the pharmacokinetics (PK) of vorasidenib following a single oral dose of 40 mg vorasidenib in healthy adult subjects (substudy A) * To evaluate the effect of multiple-dose ciprofloxacin (strong cytochrome P450 \[CYP\]1A2 inhibitor) on the single-dose PK of vorasidenib in healthy adult subjects (substudy B)

Conditions

  • Healthy Subjects

Interventions

  • Vorasidenib 40 mg Oral TabletDrug

    Single oral dose of 1×40 mg vorasidenib tablet administered : * under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing. * or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)

  • Ciprofloxacin 500 mg Oral TabletDrug

    Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)

  • Vorasidenib 10 mg Oral TabletDrug

    Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of Vorasidenib (substudy A)Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
  2. Tmax of Vorasidenib (substudy A)Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
  3. AUC0-t of Vorasidenib (substudy A)Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
  4. AUC0-inf of Vorasidenib (substudy A)Time frame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
  5. Cmax of Vorasidenib (substudy B)Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
  6. Tmax of Vorasidenib (substudy B)Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
  7. AUC0-t of Vorasidenib (substudy B)Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.
  8. AUC0-inf of Vorasidenib (substudy B)Time frame: Before dosing and at multiple time points up to 504 hours on Day 22 after administration of vorasidenib.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Development

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.